Moneycontrol PRO
UPCOMING EVENT:Watch India’s Best Managed Companies 2021, Deloitte’s global marquee programme for private companies on 17th Sept, 12 pm. Register Now!
you are here: HomeNewscoronavirus

Coronavirus India update | Mylab gets ICMR nod for its antigen testing kit for COVID-19 

Pathocatch COVID-19 Antigen Rapid testing kit will be available for orders immediately and will be priced around Rs 450.

July 23, 2020 / 08:40 AM IST
Representative image

Representative image

Pune-based Mylab Discovery Solutions on Wednesday said it has received commercial approval from the Indian Council for Medical Research (ICMR) for its antigen testing kit for COVID-19. The product named, 'Pathocatch COVID-19 Antigen Rapid testing kit', is developed and manufactured in India, Mylab said in a statement.

The kit will be available for orders immediately and will be priced around Rs 450, it added. The development adds another product to the company's suite of testing solutions for COVID-19 virus, Mylab said.

Track this LIVE blog for the latest update on coronavirus pandemic

"After bringing an affordable RT-PCR test to reduce dependence on foreign kits, we launched Compact XL to accelerate COVID-19 testing. Now, with the approval for an antigen testing kit, we will cover whole spectrum of COVID-19 testing and leave no stone unturned to fight this pandemic," Mylab Discovery Solutions MD Hasmukh Rawal said.

Health experts believe that to keep up with the pace of infections, India needs a combination of both antigen and RT-PCR testing, the statement said.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Click here for Moneycontrol's coverage of the COVID-19 outbreak
first published: Jul 23, 2020 08:39 am

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark